Global competent cells market is expected to reach USD 2,318.6 million by 2023, at a CAGR of 10.0% during the forecast period of 2018 to 2023.
Succeeding an extensive secondary and primary research on competent cells and in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraint, opportunities, and challenges in the market dynamics segment.
Transformation is a process which includes direct uptake of DNA released into an environment by host cells and simultaneously integrates that DNA with host genome for recombination. Naturally, many bacteria have an ability to take up DNA from environment. The DNA provides nutrients to these natural competent cells, while recombination leads to new genetic evolution. This ability to take up external DNA is referred as natural competence. However, not all bacteria are naturally competent; thereby reduces the chances of recombinational development. Hence, by using this concept, researchers developed artificial competence, where the cells are made competent using induced methods such as electroporation or chemicals mediated methods.
Growing demand for recombinant proteins and molecular cloned products, advancement in molecular cloning research with emergence of new technologies, and various government initiatives and availability of funding for life science research are the key drivers propelling the industry growth during the forecast period. Moreover, emerging economies such as Latin America, Asia Pacific, & Africa provides significant opportunity in this market. However, factors such as high cost of cloning based research and shortage of skilled professionals for handling of competent cells hinder the growth of this market in many parts of the globe.
The study offers a comprehensive analysis of competent cells market with respect to various segments on the basis of type, treatment, application, and end user. The competent cells market is categorized on the basis of type (cloned competent cells, Agrobacterium tumefaciens competent cells, and expression competent cells), treatment (chemically competent cells and electrocompetent cells), application (cloning, protein expression, others), and end user (pharmaceutical & biotechnology industry, academic & research institutes, and contract research organizations). The cloned competent cells commanded the largest share in the global competent cells market in 2017. This is mainly attributed to rising adoption of cloned competent cells in research with increasing feasibility of genetic therapy, growing need for rapid diagnosis & treatment, favorable government support for cloning based research in various countries, and rising availability of sophisticated instruments and technology.
Further, an in-depth analysis of the geographic scenario of the industry provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. The geographic analysis provides detailed insights on the key trends of the industry in the listed regions & countries, identifying the demographic & economic impact, and government & private investments. The geographic analysis section also comments on the key market players shaping the growth of the industry in the respective countries. Geographically, North America commanded the largest share in the global competent cells market in 2017. This was due to well-established healthcare system in the region, higher acceptance of advanced technologies, raising non-communicable diseases & related rise in pharmaceutical research & development, increase in cloning based research, and presence of many key players in this region.
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2014-2017). The key players in the global competent cells market are Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Merck & Company, Inc., Illumina, Inc., Promega Corporation, New England Biolabs, OriGene Technologies, Inc., Zymo Research Corporation, Scarab Genomics, LLC, Meridian Bioscience, Inc., Delphi Genetics S.A., Qiagen N.V., Cell Applications, Inc., GenScript Biotech Corporation, and Takara Holdings Inc.
Scope of the report
Market by Type:
- Cloned Competent Cells
- Agrobacterium tumefaciens Competent Cells
- Expression Competent Cells
Market by Treatment:
- Chemically Competent Cells
- Electrocompetent Cells
Market by Application:
- Subcloning & Routine Cloning
- Toxic/Unstable DNA Cloning
- High-Throughput Cloning
- Phage Display Library production
- Protein Expression
- Single Stranded DNA Preparation
- Mutagenesis Study
- Large Plasmid Transformation
- Lentiviral Vector Production
Market by End User:
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research Organizations
Market by Geography:
- North America
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- South Korea
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa